Enhancing Early Detection
Georgia State researchers have developed a new way to more effectively diagnose and treat cancers
A new technique developed at Georgia State has shown to be an accurate and non-invasive method to trace changes in cancers and treatment without using radiation.
Led by Jenny Yang, Distinguished University Professor and associate director of the Center for Diagnostics and Therapeutics, researchers developed a new imaging agent they named ProCA1.GRPR and demonstrated that it leads to strong tumor penetration and is capable of targeting the gastrin-releasing peptide receptor expressed on the surface of diseased cells, including prostate, cervical and lung cancer.
“ProCA1.GRPR has a strong clinical translation for human application and represents a major step forward in the quantitative imaging of disease biomarkers without the use of radiation,” Yang said. “This information is valuable for staging disease progression and monitoring treatment effects.”
The researchers’ results are an important advancement for molecular imaging with a unique ability to quantitatively detect expression level and spatial distribution of disease predictors without using radiation.
Improved imaging agents such as ProCA1.GRPR have implications in understanding disease development and treatment.
The study was funded by the National Institutes of Health, the University of Georgia Bio-imaging Research Center and Georgia Research Alliance Ventures.